Nature Reviews Cardiology, Published online: 16 October 2025; doi:10.1038/s41569-025-01222-2In this Review, Zhao and colleagues summarize the major challenges in the implementation of preventative strategies for cardiovascular disease in China and discuss the potential value of digital health-care and artificial intelligence technologies in overcoming these challenges.

Nature Reviews Cardiology, Published online: 13 October 2025; doi:10.1038/s41569-025-01224-0In patients with chronic coronary syndrome and an indication for oral anticoagulation, whether continuation of antiplatelet therapy in the initial phase after percutaneous coronary intervention is appropriate in Western populations with high atherothrombotic risk was previously unclear. The AQUATIC trial now shows that continuation of antiplatelet therapy increases the risk of both bleeding and ischaemic events in these patients.

Nature Reviews Cardiology, Published online: 06 October 2025; doi:10.1038/s41569-025-01220-4In this Review, Nicholas Chew and colleagues use epidemiological data on the cardiovascular–liver–metabolic disease syndemic to illustrate current and future projections on the burden of these diseases and their risk factors, and propose a unified framework for integrating and implementing effective multisystem interventions to tackle key components of this syndemic.

Nature Reviews Cardiology, Published online: 01 October 2025; doi:10.1038/s41569-025-01212-4In this Review, Paterson and colleagues describe how bioelectronic approaches involving site-specific targeting of the autonomic nervous circuit could be used to treat cardiovascular disease, and reflect on current bioelectronic modalities, their limitations and future ways to improve therapeutic efficiency.

Nature Reviews Clinical Oncology, Published online: 09 October 2025; doi:10.1038/s41571-025-01080-4Patients with unresectable stage III non-small-cell lung cancer without EGFR or ALK mutations typically receive the PACIFIC regimen — concurrent chemoradiotherapy (cCRT) followed by consolidation with durvalumab — whereas those with EGFR-mutant disease typically receive cCRT followed by an EGFR inhibitor. Nonetheless, a subset of patients within this heterogeneous group might be able to completely avoid consolidation therapy, whereas others are unable to tolerate cCRT. In this Review, the authors describe the standard-of-care approach in this setting, followed by discussions of treatment optimization for specific subgroups, as well as important future research questions.

Nature Reviews Clinical Oncology, Published online: 08 October 2025; doi:10.1038/s41571-025-01079-xEpstein–Barr virus (EBV) infection has a key aetiological role in endemic nasopharyngeal carcinoma (NPC). The authors of this Review discuss advances in NPC screening, which leverage the detection of either plasma EBV DNA or serum antibodies targeting EBV antigens, as well as in prevention, which relies on prophylactic and therapeutic vaccines for NPC.

Nature Reviews Clinical Oncology, Published online: 03 October 2025; doi:10.1038/s41571-025-01077-zPatients with advanced-stage pancreatic ductal adenocarcinoma often have dismal outcomes, despite an initial response sometimes to standard-of-care chemotherapy. This treatment refractoriness partly reflects the effects of the tumour microenvironment (TME), which is highly heterogeneous but can include a dense desmoplastic stroma as well as various immune cell and cancer-associated fibroblast populations, most of which collectively promote resistance to treatment and disease progression. In this Review, the authors summarize the role of the TME in determining the outcomes of patients with pancreatic ductal adenocarcinoma, and consider novel therapeutic approaches that might promote the development of a tumour-suppressive TME.

Nature Reviews Clinical Oncology, Published online: 26 September 2025; doi:10.1038/s41571-025-01082-2ALASCCA: an aspirin a day keeps colorectal cancer away